This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aratana Therapeutics Appoints Erick Lucera Vice President Of Corporate Development

KANSAS CITY, Kan. and NEW YORK, Jan. 24, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced the appointment of Erick Lucera as Vice President of Corporate Development.  Mr. Lucera will leverage his broad experience managing investments in healthcare, as well as his network of industry contacts to facilitate business development and investment initiatives for Aratana.

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "Erick is well known in the healthcare industry and we are very excited to add him to our team.  His deep understanding of corporate strategy and proven ability to recognize and invest strategically in strong growth opportunities will be paramount to keeping Aratana on its current trajectory."

Mr. Lucera stated, "Aratana represents one of the most attractive investment models I've seen in my 15 years as a healthcare investor.  I am confident the human health industry is beginning to recognize the strategic importance and remarkable value in developing animal health strategies for their assets.  As part of my commitment to positioning Aratana as the partner of choice for these companies, I look forward to bringing in high-quality assets and delivering significant value through successful execution on our business initiatives."

Erick Lucera Mr. Lucera has more than 15 years of diverse experience in the healthcare public equity markets.  Prior to joining Aratana, Mr. Lucera spent four years as Vice President and Healthcare Analyst at Eaton Vance Investment Managers.  From 2004 to 2007, Mr. Lucera was a Portfolio Manager at Intrepid Capital, where he successfully constructed and managed a portfolio constructed across biotech, pharmaceutical, device, and service companies.  Prior to that, Mr. Lucera held various leadership positions at Independence Investments, including Head of Healthcare Research.  Mr. Lucera began his career as a staff auditor and accountant at PwC.  He holds a CPH in public health from Harvard University, and M.S.F. in quantitative finance from The Wallace E. Carroll Graduate School of Management of Boston College, an MBA from Indiana University Bloomington and a B.S. in accounting from Lerner College of Business and Economics of University of Delaware.

About Aratana TherapeuticsAratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

For Investors & Media: Joshua Drumm, Ph.D. / Andrew MielachTiberend Strategic Advisors, Inc.(212) 827-0020   jdrumm@tiberend.com    amielach@tiberend.com

SOURCE Aratana Therapeutics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs